CN106455542A - 用于人造血干/祖细胞的离体扩增的组合物和方法 - Google Patents

用于人造血干/祖细胞的离体扩增的组合物和方法 Download PDF

Info

Publication number
CN106455542A
CN106455542A CN201580027546.9A CN201580027546A CN106455542A CN 106455542 A CN106455542 A CN 106455542A CN 201580027546 A CN201580027546 A CN 201580027546A CN 106455542 A CN106455542 A CN 106455542A
Authority
CN
China
Prior art keywords
cells
cell
hematopoietic
methods
nuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580027546.9A
Other languages
English (en)
Chinese (zh)
Inventor
柴力
立津央
丹尼尔·杰弗里·特南
詹姆斯·艾略特·布拉德讷
亚历山大·费德拉提恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Brigham and Womens Hospital Inc
Dana Farber Cancer Institute Inc
Original Assignee
National University of Singapore
Brigham and Womens Hospital Inc
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, Brigham and Womens Hospital Inc, Dana Farber Cancer Institute Inc filed Critical National University of Singapore
Priority to CN202010354554.7A priority Critical patent/CN112063586A/zh
Publication of CN106455542A publication Critical patent/CN106455542A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
CN201580027546.9A 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法 Pending CN106455542A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010354554.7A CN112063586A (zh) 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970787P 2014-03-26 2014-03-26
US61/970,787 2014-03-26
PCT/US2015/022557 WO2015148716A1 (en) 2014-03-26 2015-03-25 Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010354554.7A Division CN112063586A (zh) 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法

Publications (1)

Publication Number Publication Date
CN106455542A true CN106455542A (zh) 2017-02-22

Family

ID=54196365

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580027546.9A Pending CN106455542A (zh) 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法
CN202010354554.7A Pending CN112063586A (zh) 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010354554.7A Pending CN112063586A (zh) 2014-03-26 2015-03-25 用于人造血干/祖细胞的离体扩增的组合物和方法

Country Status (5)

Country Link
US (2) US20170173083A1 (https=)
EP (2) EP3122181A4 (https=)
JP (3) JP2017511132A (https=)
CN (2) CN106455542A (https=)
WO (1) WO2015148716A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109207426A (zh) * 2018-09-17 2019-01-15 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN109207427A (zh) * 2018-09-17 2019-01-15 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN109536447A (zh) * 2018-12-28 2019-03-29 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593714A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593716A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593715A (zh) * 2018-12-28 2019-04-09 北京协科医药科技有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109706119A (zh) * 2018-04-13 2019-05-03 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110592017A (zh) * 2019-07-12 2019-12-20 中国医学科学院血液病医院(中国医学科学院血液学研究所) 组蛋白甲基转移酶抑制剂在制备促进巨核细胞增殖或血小板产生的产品中的用途
CN110799641A (zh) * 2018-04-13 2020-02-14 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
CN112584845A (zh) * 2018-07-05 2021-03-30 伦波治疗有限公司 用于调节髓过氧化物酶(mpo)表达的方法和组合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
AU2016261358B2 (en) 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105238758A (zh) * 2015-09-17 2016-01-13 中国科学院广州生物医药与健康研究院 一种体外获得造血干/祖细胞的方法
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017161001A1 (en) * 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3024273A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN106119204A (zh) * 2016-06-20 2016-11-16 何力丰 一种可用于干细胞和基因治疗的改造细胞的基因技术
KR102522572B1 (ko) * 2016-08-18 2023-04-17 내셔널 유니버시티 오브 싱가포르 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체
WO2018203855A2 (en) 2016-11-16 2018-11-08 Yedi̇tepe Üni̇versi̇tesi̇ A combination inhibiting meis proteins
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US20210214699A1 (en) * 2018-07-05 2021-07-15 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN114958744A (zh) * 2022-07-12 2022-08-30 上海派思维新生物医药科技有限公司 一种离体干细胞扩大培养方法和应用
CN120769905A (zh) 2023-01-20 2025-10-10 国立大学法人熊本大学 培养基、制造方法、及细胞制剂
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276793A1 (en) * 2002-11-15 2005-12-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20080317694A1 (en) * 2000-01-21 2008-12-25 Cognis Deutschland Gmbh & Co. Kg Deodorizing Preparations
US20130136722A1 (en) * 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
US20140017212A1 (en) * 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2023912A2 (en) * 2006-05-26 2009-02-18 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2745073A1 (en) * 2008-12-03 2010-06-10 Li-Huei Tsai Inhibition of hdac2 to promote memory
PT2760994T (pt) * 2011-09-30 2017-08-24 Bluebird Bio Inc Compostos para melhor transdução viral
RU2650811C2 (ru) * 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
SI2890780T1 (sl) * 2012-08-29 2020-11-30 Sangamo Therapeutics, Inc. Postopki in sestavki za zdravljenje genetskega stanja
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317694A1 (en) * 2000-01-21 2008-12-25 Cognis Deutschland Gmbh & Co. Kg Deodorizing Preparations
US20050276793A1 (en) * 2002-11-15 2005-12-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20130136722A1 (en) * 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
US20140017212A1 (en) * 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109706119A (zh) * 2018-04-13 2019-05-03 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110799641A (zh) * 2018-04-13 2020-02-14 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN112584845A (zh) * 2018-07-05 2021-03-30 伦波治疗有限公司 用于调节髓过氧化物酶(mpo)表达的方法和组合物
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
CN109207427A (zh) * 2018-09-17 2019-01-15 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
TWI785273B (zh) * 2018-09-17 2022-12-01 大陸商諾未科技(北京)有限公司 一種用於促進造血祖細胞向造血幹細胞轉變的組合物及其培養體系
CN109207426A (zh) * 2018-09-17 2019-01-15 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN110972481B (zh) * 2018-09-17 2020-10-20 诺未科技（北京）有限公司 一种组合物及其用途
CN110972481A (zh) * 2018-09-17 2020-04-07 诺未科技（北京）有限公司 一种组合物及其用途
CN109593716A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593715A (zh) * 2018-12-28 2019-04-09 北京协科医药科技有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593715B (zh) * 2018-12-28 2020-12-08 北京承诺未来科技有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593714A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593716B (zh) * 2018-12-28 2021-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109536447A (zh) * 2018-12-28 2019-03-29 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110592017A (zh) * 2019-07-12 2019-12-20 中国医学科学院血液病医院(中国医学科学院血液学研究所) 组蛋白甲基转移酶抑制剂在制备促进巨核细胞增殖或血小板产生的产品中的用途

Also Published As

Publication number Publication date
CN112063586A (zh) 2020-12-11
EP3122181A1 (en) 2017-02-01
US20170173083A1 (en) 2017-06-22
JP2020124212A (ja) 2020-08-20
JP2022113722A (ja) 2022-08-04
US20200121721A1 (en) 2020-04-23
EP3122181A4 (en) 2018-04-25
JP2017511132A (ja) 2017-04-20
WO2015148716A1 (en) 2015-10-01
EP3777534A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
CN106455542A (zh) 用于人造血干/祖细胞的离体扩增的组合物和方法
JP7078673B2 (ja) 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
HK40038122A (en) Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
AU2014202016B2 (en) Conditionally immortalized long-term stem cells and methods of making and using such cells
Lee Extrinsic regulation of Hematopoietic Stem Cells in the fetal liver
Marcoux RET-altered Induced Pluripotent Stem Cells (iPSCs) for modeling Hematopoiesis and Non-Small Cell Lung Cancer (NSCLC)
WO2026013575A1 (en) Modeling developmental hematopoietic niches of human embryo for near-physiological blood stem cell expansion ex vivo
WO2026026711A1 (zh) 一种低免疫原性诱导多能干细胞及其诱导的造血干/祖细胞的制备方法及其应用
Anselmi Human dendritic cell development from induced-pluripotent stem cells
Tan et al. Hematopoietic stem cells and somatic stem cells
Sekulovic Characterization of mouse hematopoietic stem cells primed to actively self-renew by NUP98-HOXA10hd fusion gene

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222